Low-Dose Naltrexone
Also known as LDN
Non-peptide adjunct: compounded microdoses of naltrexone studied for inflammatory modulation, recovery quality, and chronic symptom support.
Mechanism of action
How Low-Dose Naltrexone works
Transient low-dose opioid-receptor blockade upregulates endogenous endorphin signaling and modulates glial and immune activity, distinct from full-dose naltrexone therapy.
Areas of study
What Low-Dose Naltrexone is studied for
- check
Inflammatory and pain modulation in chronic conditions
- check
Adjunctive support in autoimmune and fatigue contexts
- check
Sleep and recovery quality
Considerations
Important things your physician will discuss
This is general clinical context — not medical advice. Your evaluation determines whether Low-Dose Naltrexone is appropriate for you.
- info
Incompatible with opioid medications — combining can precipitate withdrawal; disclose all current prescriptions
- info
Compounded low-dose strengths differ from the FDA-approved 50 mg tablet and its labeled indications
- info
Vivid dreams or transient sleep changes are common in the first weeks of therapy
Related peptides
More from the Longevity category
NAD+ / NMN protocols
Co-factor and precursor protocols that target NAD+ availability, involved in mitochondrial energy production and DNA repair.
View peptide arrow_outwardEndogenous antioxidant tripeptideGlutathione
The body’s primary intracellular antioxidant, offered as an injectable protocol to support oxidative-stress defense and recovery.
View peptide arrow_outwardCurious whether this peptide fits your protocol?
A licensed Allora physician will review your goals, history, and labs before recommending any therapy.